Injection Pen Global Market Report 2018-2022 – Patent Expiry of Biologics to Drive the Demand for Biosimilars

The global injection pen market is expected to reach USD 41.38 billion by 2022 from an estimated USD 30.97 billion in 2017, at a CAGR of 6% during the forecast period.

Growing prevalence of chronic diseases across the globe, increasing number of regulatory approvals, and favorable reimbursements are expected to drive the growth of the injection pen market. However, preference for alternative drug delivery modes and poor reimbursement scenario in developing countries is expected to restrain the growth of this market to a certain extent.

Based on type, the market is segmented into disposable and reusable injection pens. The disposable injection pens segment is expected to grow at the highest CAGR during the forecast period. This can be attributed to the benefits that these pens offer, such as portability, ease of use, and a lower possibility of infection.

Based on therapy, the global injection pen market is segmented into diabetes, growth hormone therapy, osteoporosis, fertility, and other therapies. The diabetes segment is expected to grow at the highest CAGR during the forecast period. The high growth of the segment can be primarily attributed to the large diabetic population and favorable reimbursements for diabetic treatments in developed countries. The diabetes segment is further segmented into Insulin and GLP-1.

North America is expected to witness the highest growth during 2017 to 2022. The highest growth rate of the North American market is attributed to the rising prevalence of diabetes in the US and Canada, a favorable reimbursement scenario, and the increasing number of awareness programs in that region.

The key players in the global injection pen market are Novo Nordisk (Denmark), Eli Lilly (US), and Sanofi (France), Merck (US), Ypsomed (Switzerland), AstraZeneca (UK), F.Hoffman-La Roche (Switzerland), Becton Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), Pfizer (US), and Haselmeier (Switzerland).

Market Dynamics

Drivers

• Growing Prevalence of Chronic Diseases
• Increasing Number of Regulatory Approvals
• Favorable Reimbursement and Government Support

Restraints

• Preference for Alternative Drug Delivery Modes
• Poor Reimbursement Scenario in Developing Countries

Opportunities

• Patent Expiry of Biologics to Drive the Demand for Biosimilars

Challenges

• Needle-Stick Injuries & Misuse of Injection Pen

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Injection Pen Market, by Type

7 Injection Pen Market, by Therapy

8 Injection Pen Market, by End User

9 Injection Pen Market, by Region

10 Competitive Landscape

11 Company Profiles

• Astrazeneca
• Becton, Dickinson and Company (BD)
• ELI Lilly and Company
• F.Hoffman-La Roche
• Haselmeier
• Merck
• Novartis
• Novo Nordisk
• Owen Mumford
• Pfizer
• Sanofi
• Ypsomed

For more information about this report visit https://www.researchandmarkets.com/research/pqddsg/injection_pen?w=5

Media Contact:

Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/injection-pen-global-market-report-2018-2022—patent-expiry-of-biologics-to-drive-the-demand-for-biosimilars-300608876.html

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com